The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
https://www.telegraph.co.uk/investing/shares/questor-healthcare-trust-has-taken-pounding-now-turning-corner/
.....healthcare stocks continue to trade at a substantial discount to the American stock market, while biotech valuations are at a 20-year low.
Borho says he suspects that acquisitive companies will be drawn to these cheap-looking stocks, which should lift valuations.
Https://twitter.com/boy_cellar/status/1516053492003184644/photo/1
If AstraZeneca are willing to pay $6.9b for a share of the rights to the breast cancer chemo drug Enhertu, just imagine what the price will be for Avacta's whole Precision platform, with a pipeline of repurposed chemo drugs?
Losing her is the hardest thing you have ever been through and, thanks to Hargreaves Lansdown, this mourning period has been made even more unbearable.
The thought of you lugging your cases from hotel room to Airbnb lets while grieving is completely horrific. I’m so terribly sorry for what you have been through.
Rarely have I seen such hapless incompetence as Britain’s biggest investment broker has displayed here. And the timing? Well, it could not have been worse. You provided everything it should have needed to grant you access to this Isa from the beginning, yet Hargreaves Lansdown simply could not get its head around the Norwegian processes.
When I contacted the firm it admitted that it had not exactly covered itself in glory.
It said your case was “highly complicated”, as your wife’s Norwegian documents didn’t directly align with its normal requirements.
While it might have been challenging for the company to get to grips with foreign documentation, it should have been capable of figuring out what a Norwegian financial institution would have accepted as proof of your wife’s death and used that.
Happily, following my involvement and in acknowledgement of the time it has taken to get to this stage, it has agreed to make a departure from its usual requirements for when a customer dies.
It will accept the Norwegian documents along with a certified copy of your wife’s will, which you can easily obtain. This is instead of a UK grant of probate, which it would usually require for an estate of this size.
In addition, the firm has promised to conduct a full review of its actions and will ensure you are not financially disadvantaged in any way. So you will be suitably compensated for the delays and errors on its part and for the additional stress that this will have caused.
As you have been living out of hotels and Airbnbs for the past few months I would expect the bills to now be paid by Hargreaves Lansdown, as well as compensation for investment losses suffered while you have been unable to trade.
Ahead of its full review, the firm has already waived the £667 account fee that would have accrued on your wife’s account since it was notified of her death.
All told, I would expect your compensation to run into the thousands, which is the very least you deserve after this sorry fiasco.
I’m so glad, dear reader, that your money is finally on its way. When you get it you say you plan to settle in a beautiful town in the north of England, where you will buy a house.
Although life will never be the same without your wife, I hope that in time you will be very happy there. I wish you all the best.
'My wife died and I'm living out of a suitcase because Hargreaves Lansdown locked her £200k Isa'
When a reader’s wife died in her native Norway, Hargreaves Lansdown would not accept Norwegian documents as proof of her death
Katie Morley
Consumer Champion
10 April 2022 • 5:00am Katie Morley
Has a company treated you unfairly? Our Consumer Champion is available to help. For how to contact her click here.
Dear Katie,
I’m living out of a suitcase because I can’t access my late wife’s £200k Hargreaves Isa.
My wife of nearly 30 years died of cancer at the end of May last year. In spite of the pandemic, we had made it to her homeland, Norway, so she was able to see her children one last time.
Because my wife died in Norway, was a Norwegian citizen and, at the time of her death, was registered as living in Norway, all aspects of her death were dealt with by the Norwegian authorities.
I was handed something called an Uskifteattest (certificate of undivided estate), a financial document which stated that I, her surviving spouse, had taken over her estate.
This allowed me access to her Norwegian bank account. However, I am having terrible trouble getting access to her Hargreaves Lansdown Isa in Britain.
It is blocking me from the account – which contains around £200,000 – money that I desperately need. But it has not said exactly why. Since August last year it has put obstacles in my path and has lost various documents I have sent it. Now, as I approach the anniversary of my wife’s death, I am no further forward.
Hargreaves Lansdown keeps changing its mind about what it wants from me.
Now it is insisting on seeing an original death certificate, but this does not exist in Norway. More recently, it has asked to see a Norwegian grant of probate; this does not exist either.
There seems to be a complete lack of willingness to accept the documents I have provided. On March 1 I got so desperate that I sent the company a letter with a picture of my wife’s gravestone enclosed. Perhaps they don’t believe she is dead?
In October 2020, before we knew that my wife had cancer, we had sold our house in Britain and put our things into storage.
Our plan had been to move back to Norway and retire there. Unfortunately, her illness took over at such an alarming rate that the plan never took shape. Practically all our things are still in that storage unit.
After my wife’s death I ended up staying at my sister-in-law’s house, living out of a suitcase. Then I returned to Britain for a while and lived in a hotel. I am currently in an Airbnb let.
I cannot afford to buy a new home without my wife’s Hargreaves Lansdown money and I desperately need to move on with my life.
– LG, via email
Dear Reader,
You were in your early 40s when you met your wife on a rambling weekend while she was teaching English as a foreign language. For three decades you were inseparable, but then she was ripped away from you by cancer. Losing her is the hardest thin
https://www.reuters.com/business/energy/exclusive-chinas-oil-champion-prepares-western-retreat-over-sanctions-fear-2022-04-13/
China's top offshore oil and gas producer CNOOC Ltd. is preparing to exit its operations in Britain, Canada, and the United States, because of concerns in Beijing the assets could become subject to Western sanctions. #OOTT
://cnoocinternational.com/operations/europe/uk
Stocks to follow on Vox Markets - 13.04.22
13th Apr 2022 14:55
See more in series
Watch Now »
What the soaring inflation means for equities & stock selection. 00:00
Northbridge 09:50
Avingtrans 16:00
SourceBio International 20:05
Avacta 25:50https://www.**********.co.uk/articles/stocks-to-follow-on-vox-markets-13-04-22-468ff2b
re....I do find it baffling that the likes of FTI (Financial Media/IR) haven't been able to get much better coverage in the Financial Press since their appointment .
..agree 100%.....
simon.conway@fticonsulting.com is the man supposedly on the job....cld do with a tickle....at the very least.
https://www.linkedin.com/feed/hashtag/?keywords=aacr22
Avacta
Avacta 4,159 followers 1d •
1 day ago
Our Chief Scientific Officer Dr. Fiona McLaughlin and Chief Development Officer Neil Bell will be presenting the poster (abstract number 1815) 'AVA6000, a novel preCISION medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage' at the AACR Annual Meeting, New Orleans on Monday 1:30pm – 5:00pm CT. #AACR22
See profile for Alec D.
Alec D. out of network 3rd+ Experienced Regulatory Professional
23h
Best wishes towards a successful development of this potentially hugely important, relevant treatment.
See profile for Fiona McLaughlin
Fiona McLaughlin out of network 3rd+ Chief Scientific Officer
1d
Looking forward to meeting up with colleagues and sharing data on out Tumor Microenvironment Targeted Phase I asset AVA6000 in person in New Orleans
#AACR2022
https://twitter.com/rosolanor/status/1512435472970174470/photo/1
https://www.fdanews.com/articles/207330-nice-does-about-face-on-cost-adjusted-bavencio-but-rejects-pricey-troveldy?v=preview
Our Collaborations - 4D Pharma
https://www.4dpharmaplc.com › delivering-therapies
Bavencio is the first and only immunotherapy approved as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial ..
RAH
@RAH00084
@AACR
poster released to delegates tomorrow. I assume @avacta
shareholders will receive a copy via RNS at the same time given #AVCT confirmed it contains previously unseen preclin data. Anticipate CEO will then present this to shareholders on Monday (while CSO presents in US).
Q1 Operational Update
Block Energy plc, the exploration and production company focused on Georgia, is pleased to announce the following operations update for the three months ended 31 March 2022.
Highlights
· Over 92,000 operational man-hours worked in Q1 2022, with no lost-time incidents
· Strong exit Q1 production rate of over 630 boepd
· Q1 production of 46.1 Mboe (Q4: 34.6 Mboe) or an average of 512 boepd
· Q1 revenue of $2,361,000 (Q4: $2,550,000)
· Long-lead items received and gathering pipeline being built for well WR-B01 sidetrack
Health and Safety
92,000 operational man-hours have been worked by staff and contractors in Q1 (Q4: 110,000 hours) with no lost-time incidents.
Operations
JKT-01Z commenced production in mid-January 2022. Analysis indicates the well is in good communication with the in-place volume of 8 MMbbls associated with long-term producing well KRT-39.
Gas production from JKT-01Z was quickly tied into the gas infrastructure at well KRT-39 to support rapid monetisation. Since mid-January 2022, oil and gas production from JKT-01Z has delivered substantial additional cashflows to the Company, supporting early payback and moving the Company into being cashflow positive.
Preparations for the drilling of the side-track of well WR-B01 continue to make good progress. Many of the long-lead items required to drill two sidetracks have been purchased and already arrived in Georgia. Furthermore, construction of the pipeline from the WR-B01 to WR-38 wellsites, to enable the immediate monetisation of any gas produced from the WR-B01 sidetrack, has commenced.
Anthony Chow, CFA, Co-founder of Agronomics, presents at Master Investor Show 2022. In his talk, Anthony highlights cellular agriculture as an emerging sector, and illustrates the industry's expected developments and growth potential over the next decades. He also gives an overview of alternative protein companies that Agronomics is invested in.
To download the accompanying presentation slides please visit https://events.masterinvestor.co.uk/p...
The Master Investor Show is the UK's leading event for private investors. The 2022 event, hosted on 19 March 2022 in London, featured presentations from renowned investment experts and corporations, as well as a wide variety of exhibiting companies covering all asset classes and services relevant to private investors.
https://www.youtube.com/watch?v=WW4SuZqf9Dw&t=946s
Look at who liked the latest RNS...
https://twitter.com/boy_cellar/status/1510168902071951361
https://www.linkedin.com/in/deborah-andrew-27b79b16/recent-activity/
Sorrell's S4 Capital Audit Delay No Longer Down to Covid ...
https://www.bnnbloomberg.ca › sorrell-s-s4-capital-aud...
(Bloomberg) -- S4 Capital Plc is no longer blaming the delay in publishing its ... “While it would be too much to say that this has echoes of Wirecard, ...
https://www.abstractsonline.com/pp8/#!/10517/presentation/12283
AACR Annual Meeting 2022 Itinerary Planner Home Print Page Share Page
Session PO.ET01.06 - Drug Targets
1815 / 13 - AVA6000, a novel Precision medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage
Add to My Itinerary
April 11, 2022, 1:30 PM - 5:00 PM Section 23
. In vitro cytotoxicity assessments involving human tumor cell lines showed that AVA6000 was between 80-fold to 4,000-fold less cytotoxic compared to
doxorubicin. In several in vivo efficacy studies in tumours with high FAP levels, AVA6000 significantly decreased tumor volume and increased survival a dose-
dependent manner. In a PDX model of osteosarcoma, AVA6000 significantly decreased tumor volume while doxin orubicin haAd no significant effect. The efficacy and
tolerability profile of AVA6000 strongly support its clinical development, and a Phase I trial in patients with locally advanced or metastatic selected solid tumours in underway.
Russia has not yet demonstrated it is serious about peace talks with Ukraine and appears to be using negotiations as a tactic to play for time, a Western official said on Tuesday, adding the hope was still that a ceasefire could be agreed eventually.
"In terms of the negotiations, nothing that we have seen so far has demonstrated to us that President Putin and his colleagues are particularly serious about that, it's more of a tactical exercise in playing for time," the Western official said.
The official, speaking on condition of anonymity, added that talks were "nevertheless the best way forward in due course".
"We would hope that at some stage it would become real and lead to a ceasefire... We are sceptical that it is real just yet. Nevertheless, we do want to see a ceasefire which will emerge ultimately from a negotiation," the official said.
best remove those rose tinted spectacles.......nothing has changed...quelle surprise.....
https://twitter.com/search?q=%23Avct
7 months into the study.
1.30pm-5pm
Presenters:
Avacta Life Sciences, London
Tufts Medical School, Boston
Linden Oncology, London
Avacta Life Sciences, Boston
https://abstractsonline.com/pp8/#!/10517/